Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company, is at the forefront of developing biotherapeutics for cancer and autoimmune diseases. With a notable market cap of $1.76 billion, this U.S.-based firm is positioned within the healthcare sector, specifically focusing on biotechnology, where innovation meets potential investor rewards.

Currently trading at $23.17, Zymeworks has experienced a modest price change of 0.34 (0.01%) recently. Over the past year, its stock has fluctuated between $9.44 and $27.62, demonstrating significant volatility and potential for growth. This fluctuation could provide savvy investors with an opportunity to capitalize on its current price point, especially given the impressive…